OLYMPIA-4NCT06230224
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 37 versions: 36 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 12 words Show 4 more changesShow less
- Study completion moved earlier from May 29, 2029 to May 29, 2028
- Secondary endpoints: 22 to 21
- Primary endpoint revised
- Site details revised at 7 of 81 sites
- Notable Primary completion pushed from May 14, 2027 to May 29, 2028
- Trial status changed: Recruiting → Active, Not Recruiting
- Trial sites reduced: 101 → 81 locations
- Study completion pushed from May 14, 2027 to May 29, 2029
- Minor Study sites: 99 to 101v35
- Minor Study sites: 98 to 99v34
- Minor Study sites: 96 to 98v33
Show 30 earlier versionsHide 30 earlier versions
- Minor Study sites: 92 to 96v32
- Minor Study sites: 91 to 92v31
- Minor Study sites: 87 to 91v30
- Minor Study sites: 86 to 87v29
- Minor Study sites: 85 to 86v28
- Minor Study sites: 83 to 85v27
- Minor Study sites: 81 to 83v26
- Minor Study sites: 80 to 81v25
- Minor Study sites: 76 to 80v24
- Notable Primary endpoint revised
- Study sites: 62 to 76
- Secondary endpoints: 23 to 22
- Minor Study sites: 61 to 62v21
- Minor Study sites revised (61)v20
- Minor Site details revised at 3 of 61 sitesv19
- Minor Site details revised at 6 of 61 sitesv18
- Minor Study sites: 60 to 61v17
- Minor Study sites: 58 to 60v16
- Minor Study sites: 56 to 58v15
- Minor Study sites: 55 to 56v14
- Minor Study sites: 53 to 55v13
- Notable Eligibility criteria expanded, about 16 words
- Primary and study completion dates: Jul 6, 2027 to May 14, 2027
- Secondary endpoints revised (23)
- Study sites revised (53)
- Minor Study sites: 51 to 53v11
- Minor Study sites: 49 to 51v10
- Minor Study sites: 42 to 49v9
- Minor Study sites: 39 to 42v8
- Minor Study sites: 30 to 39v7
- Minor Study sites: 18 to 30v6
- Minor Study sites: 17 to 18v5
- Minor Study sites: 15 to 17v4
- Minor Study sites: 10 to 15
- Start date changed from estimate of Feb 5, 2024 to Feb 15, 2024
- Minor Study sites: 1 to 10v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (21)
Show 16 moreShow less
Arms and interventions
Participants will receive odronextamab monotherapy.
Participants will receive salvage therapy (ifosfamide, carboplatin, etoposide ± rituximab \[ICE ± R\], or dexamethasone, cisplatin, cytarabine ± rituximab \[DHAP ± R\], or gemcitabine, dexamethasone, cisplatin ± rituximab \[GDP ± R\]) and continue with autologous stem cell transplant (ASCT) following a complete response (CR)/partial response (PR).
Drugs: Odronextamab, Ifosfamide, Carboplatin, Etoposide, Rituximab, Dexamethasone, Cisplatin, Cytarabine, Gemcitabine
Sites
81 sites in 14 countries
Brazil 15, South Korea 12, Turkey (Türkiye) 11, Argentina 9, Taiwan 9, Malaysia 5, Spain 4, Thailand 4, Hungary 3, Australia 2, Chile 2, Colombia 2, Romania 2, Singapore 1